title: A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
abstract: Tyrosine kinase inhibitors such as sorafenib and axitinib were developed to treat malignancies, including stage IV renal cell carcinoma. Recently, we experienced a patient with pancreatic side effects from both sorafenib and axitinib. We report this case and include a discussion of the literature.
authors.affiliation: Department of Urology, Self-Defense Forces Central Hospital, Tokyo, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Yoshii
authors.forename: Koshiro
authors.initials: K
authors.lastname: Nishimoto
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shinchi
authors.forename: Shigeki
authors.initials: S
authors.lastname: Tokonabe
authors.forename: Masaya
authors.initials: M
authors.lastname: Takao
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Daido
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007191:Indazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced / Q000175:diagnosis*; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007191:Indazoles; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D000077784:Axitinib